Razelle Kurzrock: Tumor size correlates linearly with outcome after IO in rare cancer
Razelle Kurzrock, Associate Director of Clinical Research for the Medical College of Wisconsin Cancer Center, shared two recent article on X:
“Two studies on our DART trial with Megan Othus, Elad Sharon, Sandip P Patel and Young K Chae.
Tumor size correlates linearly with outcome after IO; no inflection at PR, SD, or PD. And patients with low-grade toxicity espisode dermatologic, do better.”
Title: Correlation between tumor size change and outcome in a rare cancer immunotherapy basket trial
Authors: Megan Othus, Sandip P Patel, Young K Chae, Eliana Dietrich, Howard Streicher, Elad Sharon and Razelle Kurzrock
Title: First Cycle Toxicity and Survival in Patients with Rare Cancers Treated with Checkpoint Inhibitors
Authors: Megan Othus, Sandip P Patel, Young Kwang Chae, Eliana Dietrich, Howard Streicher, Elad Sharon and Razelle Kurzrock
“We really appreciate your collaboration and expert input.”
Razelle Kurzrock, MD, is a world-renowned physician-scientist leader in precision medicine as well as in the development of novel therapeutics in the field of oncology. She is recognized for founding, developing and chairing one of the largest Phase 1 clinical trial departments globally while at the University of Texas MD Anderson Cancer Center; the central theme of the department was a personalized medicine strategy. She is also one of the pioneering trialists of the WINTHER precision medicine international trial focusing, for the first time, on transcriptomics in addition to genomics. This trial was the signature study of the Worldwide Innovative Network (WIN) consortium (Nature Medicine). She also developed and led some of the first tumor-agnostic cancer clinical trials.
More posts featuring Razelle Kurzrock.
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023